A Deal Built Around Supply and Scale

Telix will acquire 100% of ITM for US$1.65 billion upfront on a cash-free, debt-free basis, with US$1.25 billion of that paid in Telix shares priced at US$11.84 each. ITM shareholders are expected to hold about 23.7% of the combined company after closing, while Telix shareholders will hold 76.3%. Telix separately assumes US$302 million of ITM's net debt, and another US$96 million goes toward management equity rollover and transaction expenses payable by the sellers.

Up to US$700 million of the purchase price is tied to ITM-11. Of this, US$250 million depends on three FDA approvals. Approval for G1-G2 GEP-NETs by the end of 2027 would trigger US$100 million, with another US$100 million linked to a G2-G3 indication by 2030. A lung NETs approval by 2031 would add US$50 million. The remaining US$450 million is tied to ITM-11 reaching more than US$150 million in global net sales during fiscal 2030.

ITM’s Isotope Operations

The strategic appeal extends beyond ITM’s drug pipeline. Founded in 2004, ITM operates commercial-scale radioisotope manufacturing and a distribution network covering more than 65 countries. It is a key supplier of lutetium-177, an isotope used in targeted radiopharmaceutical treatments, and also has capabilities in actinium-225 and terbium-161.

ITM generated US$273 million in revenue in 2025, with revenue growing at a 40% compound annual rate between 2021 and 2025, according to the companies. Its isotope manufacturing operation is profitable and generates cash flow, giving Telix a larger role in both the production and development sides of radiopharmaceuticals.

Telix currently sources isotopes from outside suppliers. The acquisition deepens its supply chain for the isotopes its therapeutic pipeline depends on. Telix CEO Christian Behrenbruch called it a way to deepen "radioisotope security," combining the capabilities needed to deliver treatments globally.

ITM-11 Adds a Second Growth Driver

ITM also brings a late-stage therapeutic asset in ITM-11, or 177Lu-edotreotide, which targets gastroenteropancreatic neuroendocrine tumours. The treatment has completed the Phase 3 COMPETE trial, while a second Phase 3 study, COMPOSE, is fully enrolled and expected to provide an interim analysis in the first half of 2027.

If approved, ITM-11 would give Telix an additional route into the commercial therapeutic market and expand its presence in neuroendocrine tumours. The milestone structure means the asset also directly affects the eventual cost of the acquisition.

What Happens Next

Telix expects the transaction to close by the end of fiscal 2026, subject to shareholder approval, regulatory clearances and other customary conditions. Telix shareholders are expected to vote on the deal at an extraordinary general meeting in November.

The combined company is expected by management to generate more than US$1.3 billion in pro forma 2026 revenue and income, although that figure remains an estimate rather than reported combined results. The immediate test is narrower: whether ITM-11 clears its 2027 FDA deadline on schedule.